Author:
Udzhukhu V Yu,Kubylinskiy A A,Udzhukhu V Yu,Kubylinsky A A
Abstract
The goal of this study was to assess clinical efficacy and safety of Lavomax and to provide pathogenetic grounds for its
use in the complex therapy of patients suffering from genital herpes. The study subjects were 64 patients suffering from
genital herpes.
Their diagnosis was verified on the basis of ELISA and PCR results. Immunoassays revealed various disorders of immune
homeostasis and natural resistance. These results confirm that there are pathogenetic grounds to use Lavomax in the
complex therapy of genital herpes. Complex treatment with the use of Lavomax normalizes immune homeostasis and
quickly reduces clinical manifestations of herpes significantly reducing the frequency and duration of recurrences of the
disease.
Publisher
Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov
Reference13 articles.
1. Адаскевич В.П. Инфекции, передаваемые половым путем. Руководство для врачей. Н. Новгород: Медицинская книга. Издательство Нижегородской государственной медицинской академии 2004.
2. Armstrong G.L., Schillmger J., Markowitz L., et all. Incidence of herpes simplex virus type 2 infection in the United States. Air. J Epidemiol 2001; 153: 912-920.
3. Hollier L.M., Straub H. Genital herpes. Clin Evid (Online) 2011; pii: 1603.
4. Иванов О.Л., Молочков В.А., Бутов Ю.С. Кожные и венерические болезни. М.: Шико 2002.
5. Grossman J.H. Herpes simplex virus (HSV infection). Clin Obstet Gyn 2002; 25: (3): 552-562.